Metastatic Leiomyosarcoma
Also known as: Leiomyosarcoma metastatic / Metastatic leiomyosarcoma (morphologic abnormality)
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB05109 | Trabectedin | An alkylating agent approved for the treatment of unresectable or metastatic soft tissue sarcoma (liposarcoma or leiomyosarcoma). |
| Drug | Drug Name | Target | Type |
|---|---|---|---|
| DB05109 | Trabectedin | Cytochrome P450 3A4 | enzyme |
| DB05109 | Trabectedin | Cytochrome P450 2C9 | enzyme |
| DB05109 | Trabectedin | Cytochrome P450 2D6 | enzyme |
| DB05109 | Trabectedin | Cytochrome P450 2E1 | enzyme |
| DB05109 | Trabectedin | Cytochrome P450 2C19 | enzyme |
| DB05109 | Trabectedin | DNA | target |
| DB05109 | Trabectedin | Prostaglandin G/H synthase 1 | enzyme |
| Drug | Drug Name | Phase | Status | Count |
|---|---|---|---|---|
| DB11105 | Benzalkonium | 1 | Recruiting | 1 |
| DB00997 | Doxorubicin | 1 | Recruiting | 1 |
| DB12154 | Itacitinib | 1 | Active Not Recruiting | 1 |
| DB16252 | Nedisertib | 1 | Recruiting | 1 |
| DB00759 | Tetracycline | 1 | Recruiting | 1 |
| DB11945 | Avelumab | 1 / 2 | Terminated | 1 |
| DB00997 | Doxorubicin | 1 / 2 | Recruiting | 1 |
| DB12674 | Lurbinectedin | 1 / 2 | Recruiting | 1 |
| DB06589 | Pazopanib | 1 / 2 | Terminated | 1 |
| DB11836 | Sapanisertib | 1 / 2 | Terminated | 1 |
| DB05109 | Trabectedin | 1 / 2 | Terminated | 1 |
| DB11945 | Avelumab | 2 | Recruiting | 1 |
| DB08875 | Cabozantinib | 2 | Active Not Recruiting | 1 |
| DB00441 | Gemcitabine | 2 | Completed | 1 |
| DB00441 | Gemcitabine | 2 | Recruiting | 1 |
| DB06186 | Ipilimumab | 2 | Active Not Recruiting | 1 |
| DB11830 | Mocetinostat | 2 | Completed | 1 |
| DB11793 | Niraparib | 2 | Withdrawn | 1 |
| DB09035 | Nivolumab | 2 | Active Not Recruiting | 1 |
| DB00853 | Temozolomide | 2 | Active Not Recruiting | 1 |
| DB09074 | Olaparib | 2 / 3 | Recruiting | 1 |
| DB06589 | Pazopanib | 2 / 3 | Recruiting | 1 |
| DB00853 | Temozolomide | 2 / 3 | Recruiting | 1 |
| DB05109 | Trabectedin | 2 / 3 | Recruiting | 1 |